VERICEL CORPORATION Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
VERICEL CORPORATION (VCEL) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $3.65 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-26
- VERICEL CORPORATION effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $3.65M, a 65.34% increase from fiscal 2024.
- VERICEL CORPORATION effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $2.21M.
- VERICEL CORPORATION effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$497.00K.
- VERICEL CORPORATION effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$3.36M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 6 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|---|
| 2025-12-31 | $3.65M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $2.21M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$497.00K 10-K · filed 2026-02-26 | |
| 2022-12-31 | -$3.36M 10-K · filed 2025-02-27 | |
| 2021-12-31 | -$1.57M 10-K · filed 2024-02-29 | |
| 2020-12-31 | $601.00K 10-K · filed 2023-02-23 | |
| 2019-12-31 | -$2.03M 10-K · filed 2022-02-24 | |
| 2018-12-31 | -$1.71M 10-K · filed 2021-02-24 | |
| 2017-12-31 | -$5.88M 10-K · filed 2020-02-25 | |
| 2016-12-31 | -$6.65M 10-K · filed 2019-02-26 | |
| 2015-12-31 | -$5.56M 10-K · filed 2018-03-05 | |
| 2014-12-31 | -$6.77M 10-K · filed 2017-03-13 | |
| 2013-12-31 | -$5.31M 10-K · filed 2016-03-14 | |
| 2012-12-31 | -$10.02M 10-K · filed 2015-03-25 | |
| 2011-12-31 | -$6.69M 10-K · filed 2014-03-13 | |
| 2010-12-31 | -$6.49M 10-K · filed 2013-03-18 | |
| 2010-06-30 | -$4.95M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |